126 related articles for article (PubMed ID: 17803446)
21. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
Singh A; Holmes RA; Farhangi M; Volkert WA; Williams A; Stringham LM; Ketring AR
J Nucl Med; 1989 Nov; 30(11):1814-8. PubMed ID: 2478681
[TBL] [Abstract][Full Text] [Related]
22. Samarium-153-EDTMP in bone metastases.
Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
[TBL] [Abstract][Full Text] [Related]
23. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.
Loeb DM; Hobbs RF; Okoli A; Chen AR; Cho S; Srinivasan S; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
Cancer; 2010 Dec; 116(23):5470-8. PubMed ID: 20715156
[TBL] [Abstract][Full Text] [Related]
24. [Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor].
Deng H; Tan T; Mo T; Zhong S; Kuan A; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Jun; 26(2):155-9. PubMed ID: 7490021
[TBL] [Abstract][Full Text] [Related]
25. ¹⁷⁷Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases.
Shinto AS; Shibu D; Kamaleshwaran KK; Das T; Chakraborty S; Banerjee S; Thirumalaisamy P; Das P; Veersekar G
J Nucl Med Technol; 2014 Mar; 42(1):55-61. PubMed ID: 24503346
[TBL] [Abstract][Full Text] [Related]
26. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.
Dolezal J
Onkologie; 2009 Feb; 32(1-2):35-9. PubMed ID: 19209017
[TBL] [Abstract][Full Text] [Related]
28. [153Sm-EDTMP for moderate and severe bone cancer pain].
Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
[TBL] [Abstract][Full Text] [Related]
29. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
30. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
32. Comparative in vivo and in vitro study of the cytogenetic effects of 153Sm-EDTMP in lymphocytes of patients with bone metastases.
da Silva MA; Suzuki MF; Guimarães MI; Buchpiguel CA; Rogero JR; Yoriyaz H; Siqueira PT; Coelho PR; Okazaki K
Cell Mol Biol (Noisy-le-grand); 2002 Jul; 48(5):493-9. PubMed ID: 12146702
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].
Feng JY; Wu CQ; Zhang P; Wang SJ; Zheng XH
Zhonghua Nan Ke Xue; 2012 Nov; 18(11):982-5. PubMed ID: 23214246
[TBL] [Abstract][Full Text] [Related]
34. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of patients not responding to a single dose of 153Sm-EDTMP palliative treatment for painful skeletal metastases.
Tian J; Cao L; Zhang J; Ouyang Q; Hou Q; He Y
Chin Med J (Engl); 2002 Jun; 115(6):824-8. PubMed ID: 12123545
[TBL] [Abstract][Full Text] [Related]
37. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
Higano CS; Quick DP; Bushnell D; Sartor O
Clin Genitourin Cancer; 2008 Mar; 6(1):40-5. PubMed ID: 18501082
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of efficacy of 153Sm-EDTMP in patients with painful bone metastases of breast cancer].
Wu H; Tan T; Fang L; Zhang X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):716-8. PubMed ID: 14619591
[TBL] [Abstract][Full Text] [Related]
39. Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP.
Goeckeler WF; Stoneburner LK; Kasi LP; Fossella FV; Price DR; Fordyce WA
Nucl Med Biol; 1993 Jul; 20(5):657-61. PubMed ID: 8358352
[TBL] [Abstract][Full Text] [Related]
40. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.
Collins C; Eary JF; Donaldson G; Vernon C; Bush NE; Petersdorf S; Livingston RB; Gordon EE; Chapman CR; Appelbaum FR
J Nucl Med; 1993 Nov; 34(11):1839-44. PubMed ID: 8229221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
